![]() was incorporated in 2013 and is headquartered in Boston, Massachusetts. and changed its name to Decibel Therapeutics, Inc. The company was formerly known as Hearing Inc. to develop gene therapies for monogenic forms of congenital hearing loss. ![]() has a strategic collaboration with Regeneron Pharmaceuticals, Inc. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Decibel Therapeuticss valuation in October 2015 was 25.24M. Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Decibel Therapeuticss latest funding round was a IPO for 100.05M on February 12, 2021.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |